BCL2L1 and neoplasm: In this study, combination of the MEK inhibitor with ABT-263 led to a dramatic reduction of tumour growth in xenograft models of KRAS mutant tumours, supporting combined BCL-XL/MEK inhibition as a potential therapeutic approach for KRAS mutant cancers and providing a basis for stratified clinical trials.